| ASCO
The SPEARHEAD-1 trial of afamitresgene autoleucel (afami-cel [formerly |
| @Breakthewallsdown23 |
04/30/2023 5:33:59 PM |
| From FB https://www.fiercepharma.com/pharma/astellas-writes-340m-fibrogens-evren |
| @sirphoenix |
04/14/2023 1:08:05 AM |
| The company said it will regain rights to |
| @sidcorp2020 |
04/11/2023 6:54:34 PM |
| Upcoming https://annualmeeting.asgct.org/program/agenda-details?agendaId=26880 |
| @MAVTASTIK |
04/10/2023 5:52:14 PM |
| (OT) Two interesting preclinical papers https://jitc.bmj.com/content/11/4/e00551 |
| @Cessnaguy |
04/05/2023 8:56:43 PM |
| Afamitresgene autoleucel (afami-cel; formerly ADP-A2M4) demonstrates durable cli |
| @jfarrar42 |
03/15/2023 1:47:07 AM |
| Preclinical data https://journals.lww.com/immunotherapy-journal/Fulltext/9900/En |
| @kenta23 |
03/01/2023 9:34:43 PM |
| znewcar1: $ADAP 25% v1,45M c2.08 f163,3M H 2.15 S@2 ML1.02 |
| @titusdasboogas |
11/08/2022 9:49:40 PM |
| The good: There have been new responses, which |
| @jrmew00 |
11/08/2022 9:32:03 PM |
| SURPASS-3 is now listed https://clinicaltrials.gov/ct2/show/NCT05601752 |
| @InquisitiveInvestor |
11/02/2022 9:59:31 PM |
| Cell Therapies need eganelisib for TME and durability. |
| @wjphillips |
10/27/2022 7:15:44 PM |
| The results from first gen trial have been |
| @cysal |
10/25/2022 5:01:20 PM |
| $GSK is transferring back the NY-ESO-1 and PRAME |
| @CountCrypto |
10/25/2022 4:52:54 PM |
| Upcoming https://cattendee.abstractsonline.com/meeting/10720/presentation/1291 |
| @Rdautoro |
10/18/2022 9:45:04 PM |
| Yes, but they had failed a number of |
| @Jamesdlg |
09/14/2022 11:57:50 PM |
| Same as $DTIL 19A. |
| @Nicky |
09/09/2022 10:47:00 PM |
| PR https://www.biospace.com/article/adaptimmune-reports-positive-data-in-its-sur |
| @Lance |
09/09/2022 9:46:35 PM |
| The ESMO abstract is out, with an ORR |
| @villagetalkies |
09/05/2022 11:28:59 PM |
| Link to register https://bit.ly/3QBacNt |
| @giulio1957 |
08/25/2022 9:49:24 PM |
| On the 9th of Sept, the company will |
| @AlanDavid |
08/25/2022 9:47:33 PM |
| Just got in,see there is a lot of |
| @delmar65 |
07/19/2022 7:06:22 PM |
| Looks like this could run. Took a position |
| @milf |
06/03/2022 4:43:29 PM |
| NEA just ran$ GNCA to the ground. |
| @global_mkts |
05/24/2022 2:33:21 PM |
| PR https://www.globenewswire.com/news-release/2022/05/16/2444402/35803/en/Precli |
| @Apiloto62 |
05/16/2022 9:21:22 PM |
| 335: Next-Generation, Inducible IL-7-Expressing, Tumor-Infiltrating Lymphocytes |
| @securingthebagg |
05/02/2022 9:48:28 PM |
| ASGCT titles: |
| @QueenCity |
04/29/2022 11:24:56 PM |
| AACR PR https://www.globenewswire.com/news-release/2022/04/08/2419433/35803/en/A |
| @Pmc87 |
04/08/2022 7:00:52 PM |
| Also, they aim to open the allogeneic facilities |
| @SkyHill |
03/20/2022 11:54:43 PM |
| Upcoming |
| @Lazada89 |
03/20/2022 11:51:02 PM |
| New preclinical data https://www.jimmunol.org/content/early/2021/12/01/jimmunol. |
| @qtdad |
12/09/2021 10:44:48 PM |
| A trial (along with at least two others) |
| @gaylordgriswold |
12/09/2021 10:44:07 PM |
| Another, Enhanced Activity of Second-Generation MAGE-A4 SPEAR T-Cells |
| @mmgmm |
12/09/2021 10:43:03 PM |
| New preclinical data (Noile-Immune Bio's PRIME tech) https://mct.aacrjournals.o |
| @kunaladitya |
10/26/2021 9:10:05 PM |
| The ovarian patient with a confirmed CR had |
| @Disruptech2 |
09/30/2021 6:44:34 PM |
| The poster https://d1io3yog0oux5.cloudfront.net/_c4a3fd9db12be7ae245032a7178a264 |
| @diamond5 |
09/28/2021 11:22:08 PM |
| STRANGE POS |
| @Getright |
09/16/2021 11:38:03 PM |
| Here is the video https://www.youtube.com/watch?v=vXGoi-HE0CQ |
| @marketstridess |
09/15/2021 8:46:16 PM |
| Another slide |
| @Bhill |
09/13/2021 6:38:50 PM |
| Slides https://d1io3yog0oux5.cloudfront.net/_e7896ea0f6acb98530236acf35bbf90e/ad |
| @bclarkassoc |
09/13/2021 5:02:11 PM |
| New PR https://www.globenewswire.com/news-release/2021/09/13/2295608/35803/en/Ad |
| @bigburt |
09/13/2021 5:00:40 PM |
| It seems that SURPASS-2 has now opened to |
| @kapildesai |
09/10/2021 7:41:28 PM |
| ''Next week, we will post the replay of |
| @pjputnam1952 |
09/10/2021 7:40:23 PM |
| Slides from an event (I will try and |
| @salmanaziz |
09/09/2021 3:59:40 PM |
| This is hitting the radar on many platforms |
| @trkeenan |
09/09/2021 10:37:00 AM |
| bullish |
| @dirtytrumbone |
09/09/2021 12:15:08 AM |
| I agree, and the affirmation of the tech |
| @Everett |
09/08/2021 1:26:35 AM |
| carl icahn is taking a stake this week sometime |
| @iwatson |
09/07/2021 9:16:54 PM |
| znewcar1: ADAP 28% v46,3M c6.37 f156M H6.82 |
| @nishaparmar |
09/07/2021 8:10:03 PM |
| im invested at ELYS at moment |
| @alanmarchwinski |
09/07/2021 6:50:12 PM |
| beauty |
| @rlong |
09/07/2021 6:50:12 PM |
| https://www.stockscores.com/chart.asp?TickerSymbol=%20adap&TimeRange=365&Interva |
| @Mstephen23 |
09/07/2021 6:49:07 PM |
| znewcar1: ADAP 127% v112,8M c11.07 f130,0M H12.77 morning gap up preMH@ 12. open dip under $8 pushed hard @8. |
| @DAIsf |
05/29/2020 8:49:44 PM |
| znewcar1: ADAP 24% v3,1M c4.44 f130,0M H5 |
| @Darius540 |
05/08/2020 8:44:29 PM |
| znewcar1: ADAP 200% v56M c3.99 f105M gap up from 1.3 to 2.11 then shot up from there H4.62 back to 3.20 just |
| @Csail7 |
01/14/2020 12:49:33 AM |
| znewcar1: ADAP 22% v339K c1.17 f105M |
| @Lcarta |
11/29/2019 7:54:50 PM |
| znewcar1: 8$1M C$12.47 ;( fell off the radar. What a beautiful flag. This could hit $16 IMO |
| @Drharoonafridi |
04/13/2018 1:56:24 AM |
| znewcar1: +10% $11.40 with little overall vol. since it broke out four days prior. |
| @mubashermubi |
03/22/2018 3:37:41 AM |